Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited has announced a research collaboration with the George Washington University Cancer Center to initiate a Phase II trial evaluating eftilagimod alfa (efti) as a neoadjuvant therapy for early-stage HR+/HER2-negative breast cancer. The trial will explore efti’s potential to activate a broad anti-cancer immune response, potentially leading to high pathologic complete response rates and improved disease-free survival. This collaboration allows Immutep to expand its clinical pipeline cost-effectively and further positions efti as a promising immunotherapy in both metastatic and neoadjuvant cancer settings.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, which are designed to stimulate or suppress the immune response. Immutep’s diversified product portfolio aims to provide innovative treatment options for patients and maximize shareholder value.
YTD Price Performance: -31.51%
Average Trading Volume: 2,651,944
Technical Sentiment Signal: Sell
Current Market Cap: A$367M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.